Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of Gimatecan in Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT04029909Phase 1Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gimatecan in ovarian epithelial cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (3 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoint: Dose limiting toxicity at 28 days. Status: unknown.
02
Drugs
gimatecan
03
Conditions
ovarian epithelial cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04029909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04029909.